Safety and Efficacy of Sintilimab Combined With Anlotinib in Patients With KRAS Mutant Advanced /Metastatic Non-Small Cell Lung Cancer: a Prospective, Single-Arm Study
Latest Information Update: 29 Aug 2024
Price :
$35 *
At a glance
- Drugs Catequentinib (Primary) ; Sintilimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Aug 2024 According to an Innovent Biologics media release, data from this trial will be presented at the at World Conference on Lung Cancer (WCLC) from Sept 7-10, 2024, in San Diego, U.S.
- 04 Aug 2020 New trial record